Homeopathic Treatment of Fatigue in Children Receiving Chemotherapy
NCT01662076 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2015-05-20
Summary
Cancer-related fatigue has been described as a subjective feeling of physical, emotional, and/or cognitive tiredness. Fatigue is frequently identified as one of the most troublesome symptoms in pediatric cancer patients. Fatigue affects children with cancer throughout the trajectory of their disease. Treatment interventions for cancer-related fatigue have been largely unsuccessful. Homeopathy involves treatment of patients with diluted natural substances aimed at stimulating the body's healing system. In the efficacy trial literature, individualized homeopathy shows the most promise over other forms of homeopathic intervention. Individualized homeopathic treatment involves a unique yet established method of case taking. During the consultation, the homeopath asks a series of broad questions to elicit subjective symptoms related to the patient's disease, their medical history, as well as particular characteristics (physical or psychological) related to the individual. This study will recruit children receiving chemotherapy to undergo homeopathic remedies to treat their fatigue. This study hypothesizes that homeopathic treatment will effectively treat fatigue.
Conditions
Interventions
- OTHER
-
Homeopathic Remedies
The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
Sponsors & Collaborators
-
The Hospital for Sick Children
lead OTHER
Principal Investigators
-
Lillian Sung, MD · The Hospital for Sick Children
Study Design
- Allocation
- NA
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-08-31
- Primary Completion
- 2014-05-31
- Completion
- 2014-05-31
Countries
- Canada
Study Locations
More Related Trials
-
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
NCT00016861 ·Status: COMPLETED ·Phase: PHASE1
-
Parent/Child Dyad Approach to Symptom Screening for Children With Cancer
NCT05012917 ·Status: COMPLETED ·Phase: NA
-
Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy
NCT00001565 ·Status: COMPLETED ·Phase: PHASE1
-
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
NCT00624962 ·Status: WITHDRAWN ·Phase: NA
-
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
NCT00003745 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
NCT00004010 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of Chemotherapy on Memory Function and the Development of Traumatic Symptoms in Children With Cancer
NCT01108952 ·Status: UNKNOWN
-
Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
NCT02076997 ·Status: COMPLETED ·Phase: NA
-
Bortezomib in Treating Children With Advanced Solid Tumors
NCT00021216 ·Status: COMPLETED ·Phase: PHASE1
-
Infections in Pediatric Cancer Patients
NCT00930267 ·Status: UNKNOWN
-
Three Times Weekly Symptom Screening for Children With Cancer
NCT04275102 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
NCT00006095 ·Status: COMPLETED ·Phase: PHASE1
-
The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology
NCT01838564 ·Status: COMPLETED ·Phase: NA
-
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
NCT00417014 ·Status: UNKNOWN ·Phase: NA
-
Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
NCT01858571 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
NCT00053118 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
NCT00416377 ·Status: UNKNOWN ·Phase: NA
-
Radiation Therapy and the Natural History of Childhood Cancers
NCT00064883 ·Status: COMPLETED
-
Study of Irinotecan on a Weekly Schedule in Children
NCT00062842 ·Status: COMPLETED ·Phase: PHASE1
-
Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma
NCT03545542 ·Status: UNKNOWN ·Phase: NA
-
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
NCT00644696 ·Status: COMPLETED ·Phase: PHASE1
-
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
NCT00138216 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine in Treating Children With Refractory Solid Tumors
NCT00005577 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of MC in Paediatric Palliative Care
NCT05615389 ·Status: RECRUITING ·Phase: PHASE1/PHASE2